Search results for "Autoimmune"

showing 10 items of 648 documents

Relationship of eye muscle antibodies with HLA phenotypes and thyroid-stimulating immunoglobulins in endocrine orbitopathy.

1991

The relationship between endocrine orbitopathy and Graves' hyperthyroidism is still not clairified. The purpose of this study was to elucidate the incidence of eye muscle antibodies and the relationship with HLA phenotypes and thyroid antibodies in 65 patients with endocrine orbitopathy classes 1–5. Both bovine and abdominal muscles were used as antigens in ELISA systems in which IgG and IgM antibodies were assayed. Before starting the immunosuppressant therapy, 46/65 patients (71%) showed a positive result for eye muscle antibodies. Those patients with an active disease had such antibodies more frequently. Where the ophthalmopathy was of recent onset IgM antibodies were found, whereas pati…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesExophthalmosAdolescentmedicine.medical_treatmentAutoimmune DiseasesAntigenHLA AntigensInternal medicineMedicineExophthalmosHumansAgedAutoantibodiesAutoimmune diseasebiologybusiness.industryThyroidGeneral MedicineMiddle Agedmedicine.diseaseAnti-thyroid autoantibodiesGraves Diseasemedicine.anatomical_structureEndocrinologyPhenotypeImmunoglobulin MOculomotor MusclesImmunoglobulin GImmunologybiology.proteinThyroid Stimulating ImmunoglobulinThyroglobulinFemaleAntibodymedicine.symptombusinessImmunoglobulins Thyroid-StimulatingResearch in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie
researchProduct

Frequency and Characterization of Benign Lesions in Patients Undergoing Surgery for the Suspicion of Solid Pancreatic Neoplasm

2013

A diagnosis of benign lesions (BLs) is reported in 5% to 21% of pancreatoduodenectomies performed for neoplasms; no data for body-tail resections are available. The aims were to investigate the frequency and characterize the BLs mimicking cancer in the head and the body-tail of the pancreas.This study is a retrospective review of pancreatic specimenscollected from 2005 to 2011 in the pathology database of Mainz (Germany). Patients with final diagnosis excluding malignancy were analyzed by histology, imaging, and clinical aspects.Among 373 patients, 33 patients (8.8%) were diagnosed with a benign disease: 25 (8.4%) of 298 in the pancreatic head and 8 (10.7%) of 75 in the body-tail resections…

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmenteducationSymptom assessmentChoristomaUnnecessary ProceduresAutoimmune DiseasesDiagnosis DifferentialYoung AdultPancreatectomyEndocrinologyGermanyhemic and lymphatic diseasesDiagnosis80 and overPrevalenceInternal MedicineHumansMedicineNeoplasmIn patientAgedRetrospective StudiesAged 80 and overAdolescent; Adult; Aged; Aged 80 and over; Autoimmune Diseases; Choristoma; Diagnosis Differential; Female; Germany; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Diseases; Pancreatic Neoplasms; Pancreatitis; Prevalence; Retrospective Studies; Spleen; Symptom Assessment; Unnecessary Procedures; Young AdultHepatologybusiness.industryGastroenterologyPancreatic DiseasesCancerRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryPancreatic NeoplasmsPancreatitisDifferentialPancreatectomyPancreatitisFemaleRadiologySymptom AssessmentDifferential diagnosisbusinessSpleenPancreas
researchProduct

Early onset of polyglandular failure is associated with HLA-DRB1*03.

2008

ObjectivesPolyglandular failure or autoimmunity (PGA) involves at least two endocrine diseases. Several genes may play a role in its etiology. This study analyzed 1) whether HLA-DRB1, HLA-DQB1, and MHC class I chain-related gene A (MICA) polymorphisms are associated in PGA and 2) whether PGA patients display stronger associations with these immune genes than patients with monoglandular autoimmunity (MGA).DesignAssociation study.MethodsHLA-DRB1, HLA-DQB1, and MICA alleles were analyzed in 73 patients with PGA, 283 with MGA, and 206 healthy controls. The HLA-DRB1 and HLA-DQB1 polymorphisms were determined with PCR-amplified DNA being hybridized with PCR-sequence-specific oligonucleotide probe…

AdultMalemedicine.medical_specialtyAdolescentGenotypeEndocrinology Diabetes and MetabolismBiologymedicine.disease_causePolymerase Chain Reactionlaw.inventionAutoimmunityEndocrinologyGene FrequencylawInternal medicineGermanyHLA-DQ AntigensmedicineHLA-DQ beta-ChainsHumansGenetic Predisposition to DiseaseAlleleAge of OnsetChildPolyendocrinopathies AutoimmuneGeneHLA-DRB1Polymerase chain reactionAllelesPolymorphism GeneticHistocompatibility Antigens Class IGeneral MedicineHLA-DR AntigensMiddle AgedEndocrinologyGenetic markerMicrosatelliteFemaleAge of onsetHLA-DRB1 ChainsEuropean journal of endocrinology
researchProduct

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.

2018

Background Autoimmune thrombotic thrombocytopenic purpura (iTTP) is caused by autoantibody-mediated severe a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) deficiency leading to micro-angiopathic haemolytic anaemia (MAHA) and thrombocytopenia with organ damage. Patients survive with plasma exchange (PEX), fresh frozen plasma replacement and corticosteroid treatment. Anti-CD20 monoclonal antibody rituximab is increasingly used in patients resistant to conventional PEX or relapsing after an acute bout. Objective This retrospective observational study focused on the relapse rate and possible influencing factors including treatment with rituximab first…

AdultMalemedicine.medical_specialtyAdolescentautoantibodiesThrombotic thrombocytopenic purpuraADAMTS13 ProteinRelapse rate030204 cardiovascular system & hematologyGastroenterologyAutoimmune Diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsRecurrenceInternal medicinehemic and lymphatic diseasesCellular Haemostasis and PlateletsMedicineHumansImmunologic Factorsclinical studiesYoung adultChildADAMS/ADAMTS13Retrospective StudiesPurpura Thrombotic Thrombocytopenicbusiness.industryRetrospective cohort studyHematologythrombotic thrombocytopenic purpura (TTP/HUS)Middle Agedmedicine.diseaseAntigens CD20ADAMTS13PurpuraTreatment Outcome030220 oncology & carcinogenesisRituximabFemaleFresh frozen plasmamedicine.symptombusinessRituximabmedicine.drugFollow-Up StudiesThrombosis and haemostasis
researchProduct

The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients

1990

In autoimmune disease the functional deficiency of T suppressor cells, also described in Type I diabetes, may be restored through immunoglobulin (Ig) infusion, which increases antigen phagocytosis, NK activity, cell clones and antibody anti-idiotype responses. Sixteen Type I diabetic patients were studied: eight were treated soon after the initial correction of disease-onset glycemic deterioration with intensive intravenous (i.v.) 7S Ig treatment (0.4 g/kg/BW) for 1 week and once per week for 6 months, whilst the remaining patients constituted the control group. All patients were evaluated during the study for metabolic and immunological parameters. A reduction in insulin requirement compar…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPhagocytosisImmunologyCellAutoimmune DiseasesRandom AllocationAntigenInternal medicinemedicineHumansInsulinImmunology and AllergyChildAutoantibodiesGlycemicAutoimmune diseaseC-Peptidebiologybusiness.industryInsulinImmunization PassiveReceptors Interleukin-2medicine.diseaseDiabetes Mellitus Type 1medicine.anatomical_structureEndocrinologyIntravenous ImmunoglobulinsChild Preschoolbiology.proteinFemaleAntibodybusinessJournal of Autoimmunity
researchProduct

Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoprolif…

2010

Long term immunosuppression and therapy of acute rejections result in a 20-120-fold increased risk to develop Non Hodgkin lymphoma (NHL). Since immunosuppressive therapy and immunological disorders are major risk factors for the development of NHL in the non-transplant population we aimed to analyze risk factors for PTLD in our cohort of liver transplanted (LT) patients.We analyzed retrospectively 431 patients liver transplanted between 1998 and 2008.PTLD was diagnosed in eleven of 431 patients (2.6%). PTLD, especially late PTLD, was significantly more frequent in patients who received steroids before LT (Kaplan-Meier: p0.001). Moreover PTLD in immunocompromised patients with preoperative s…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPopulationAutoimmune hepatitisKaplan-Meier EstimateLiver transplantationGastroenterologyYoung AdultPostoperative ComplicationsRisk Factorshemic and lymphatic diseasesInternal medicinePreoperative CareInternal MedicinemedicineCadaverHumansProspective cohort studyeducationChildAgedProportional Hazards ModelsRetrospective StudiesHepatitiseducation.field_of_studybusiness.industryLymphoma Non-HodgkinRetrospective cohort studyImmunosuppressionMiddle Agedmedicine.diseaseTissue DonorsLymphomaLiver TransplantationHepatitis Autoimmunesurgical procedures operativeImmunologyMultivariate AnalysisFemaleSteroidsbusinessImmunosuppressive AgentsEuropean journal of internal medicine
researchProduct

Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.

2017

Background & Aims Controlled attenuation parameter (CAP) can be performed together with liver stiffness measurement (LSM) by transient elastography (TE) and is often used to diagnose fatty liver. We aimed to define the validity criteria of CAP. Methods CAP was measured by the M probe prior to liver biopsy in 754 consecutive patients with different liver diseases at three centers in Europe and Hong Kong (derivation cohort, n = 340; validation cohort, n = 414; 101 chronic hepatitis B, 154 chronic hepatitis C, 349 non-alcoholic fatty liver disease, 37 autoimmune hepatitis, 49 cholestatic liver disease, 64 others; 277 F3-4; age 52 ± 14; body mass index 27.2 ± 5.3 kg/m2). The primary outco…

AdultMalemedicine.medical_specialtyBiopsyAutoimmune hepatitisHepatic steatosiDiagnostic accuracyGastroenterology03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineNonalcoholic fatty liver diseaseMedicineHumansLiver stiffness measurementAgedFibroScanHepatologymedicine.diagnostic_testbusiness.industryFatty liverReproducibility of ResultsLiver biopsyHepatologyMiddle Agedmedicine.diseaseFatty LiverCross-Sectional StudiesLiverROC Curve030220 oncology & carcinogenesisLiver biopsyElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleSteatosisTransient elastographybusinessNon-alcoholic fatty liver diseaseJournal of hepatology
researchProduct

Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the E…

2021

Knowledge of living donor liver transplantation (LDLT) for autoimmune liver diseases (AILDs) is scarce. This study analyzed survival in LDLT recipients registered in the European Liver Transplant Registry with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis (PSC) and the non-autoimmune disorder alcohol-related cirrhosis. In total, 29 902 individuals enrolled between 1998 and 2017 were analyzed, including 1003 with LDLT. Survival from >90 days after LDLT for AILDs in adults was 85.5%, 74.2%, and 58.0% after 5, 10, and 15 years. Adjusted for recipient age, sex, and liver transplantation era, adult PSC patients receiving LDLT showed increased mortality compare…

AdultMalemedicine.medical_specialtyBrain DeathCirrhosisMultivariate analysis[SDV]Life Sciences [q-bio]Medizinliving donorDiseaseAutoimmune hepatitisinflammatory030230 surgeryclinical research/practiceGastroenterologyPrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicinepatient survivalInternal medicinemedicinePrimary Sclerosing CholangitisLiving DonorsImmunology and AllergyRisk-FactorsHumansPharmacology (medical)RegistriesChildRetrospective StudiesTransplantationbusiness.industryLiver DiseasesHazard ratioGraft SurvivalCohort[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.disease3. Good healthDonation after brain deathLiver TransplantationTreatment Outcome030211 gastroenterology & hepatologyimmuneMorbidityLiving donor liver transplantationbusinessliver diseaseliver transplantation/hepatologyAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsREFERENCES
researchProduct

Type I Diabetes is the Main Cost Driver in Autoimmune Polyendocrinopathy

2019

Abstract Context Autoimmune polyendocrinopathy (AP), a chronic complex orphan disease, encompasses at least two autoimmune-induced endocrine diseases. Objective To estimate for the first time total, indirect and direct costs for patients with AP, as well as cost drivers. Design Cross-sectional cost of illness study. Setting Academic tertiary referral center for AP. Patients 146 consecutive, unselected AP patients. Intervention Interviews pertaining to patients’ socioeconomic situation covered a recall period of 12 months. Both the human capital (HCA) and the friction cost approaches (FCAs) were applied as estimation methods. Main outcome measures Direct and indirect annual costs, and sick l…

AdultMalemedicine.medical_specialtyCost estimateEndocrinology Diabetes and MetabolismClinical BiochemistryContext (language use)DiseaseBiochemistryYoung AdultIndirect costsEndocrinologyCost of IllnessInternal medicinemedicineHumansPolyendocrinopathies AutoimmuneAgedType 1 diabetesbusiness.industryBiochemistry (medical)Health Care CostsAutoimmune polyendocrinopathyMiddle AgedPrognosismedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 1EndocrinologyCost driverSick leaveFemalebusinessFollow-Up StudiesThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study.

2014

Abstract Background Drugs and herbal products can induce autoimmune hepatitis. We assessed frequency and clinical outcomes of patients suffering from drug-induced autoimmune hepatitis. Methods All patients with drug-induced liver injury admitted between 2000 and 2011 were retrospectively studied. Diagnoses of drug-induced autoimmune hepatitis and idiopathic autoimmune hepatitis were made according to simplified criteria. After discharge, all patients had regular follow-up and were contacted to update outcomes. Results Among 10,270 in-hospital patients, 136 (1.3%) were diagnosed with drug-induced liver injury. Among them, 12 (8.8%) were diagnosed as drug-induced autoimmune hepatitis (41.7% m…

AdultMalemedicine.medical_specialtyDrug-induced liver injuryAdolescentAutoimmunityAutoimmune hepatitisSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyAutoimmunityYoung AdultInternal medicinemedicineHumansAutoimmunity; Drug-induced liver injury; Human leucocyte antigens; Liver biopsy --------------------------------------------------------------------------------Liver biopsy --------------------------------------------------------------------------------AgedRetrospective StudiesSettore MED/04 - Patologia GeneraleLiver injurySettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyGamma globulinRetrospective cohort studyHuman leucocyte antigenJaundiceMiddle Agedmedicine.diseaseHepatitis AutoimmuneTreatment OutcomeLiver biopsyCohortImmunologyFemalemedicine.symptomChemical and Drug Induced Liver InjurybusinessImmunosuppressive AgentsFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct